



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/621,693
Filing Date	07/16/2003
First Named Inventor	BUSSELL, Stuart
Art Unit	1646
Examiner Name	To be determined
Total Number of Pages in This Submission	4
Attorney Docket Number	GNP-00101.P.1-US

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
---	--	---

Remarks

1. Form 1449
2. 1 volume of references cited on Form 1449;
3. Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	David R Preston Reg No 38710
Signature	
Date	June 30, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Raymond Wagenknecht
Signature	
Date	6/30/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUL 02 2004

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEET TRANSMITTAL
for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 0.00)

Complete if Known

Application Number	10/621,693
Filing Date	07/16/2003
First Named Inventor	BUSSELL, Stuart
Examiner Name	To be determined
Art Unit	1646
Attorney Docket No.	GNP-00101.P.1-US

METHOD OF PAYMENT (check all that apply)

Check Credit card Money Order Other None

 Deposit Account:

Deposit Account Number	501321
Deposit Account Name	David R. Preston

The Commissioner is authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEES CALCULATION**1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)		(\$ 0.00)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Independent Claims	Multiple Dependent	Extra Claims	Fee from below	Fee Paid
			-20** =	X	=
			- 3** =	X	=

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$ 0.00)

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Small Entity


Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) **(\$ 0.00)****SUBMITTED BY**

(Complete if applicable)

Name (Print/Type)	David R. Preston	Registration No. (Attorney/Agent)	38,710	Telephone	858-724-0375
Signature					
	Date	6/30/04			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Patent
Docket Number: GNT-00101.P.1-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
)
)
 BUSSELL, Stuart) Examiner: To Be Determined
)
)
Application No.: 10/621,693) Art Unit: 1646
)
)
Filed: July 16, 2003)
)
For: METHODS TO CONSTRUCT)
 MULTIMERIC DNA AND)
 POLYMERIC PROTEIN)
 SEQUENCES AS DIRECT)
 FUSIONS OR WITH LINKERS)
)

Commissioner for Patents
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant respectfully submits this information disclosure statement before the mailing of a First Office Action on the merits under 37 C.F.R. § 1.97(a)(3). Accordingly, no fee under 37 C.F.R. § 1.17(p) is deemed necessary.

Applicant submits 1 volume of references listed on the attached Form 1449.

Information Disclosure Statement
GNT-00101.P.1-US
BUSSELL, Stuart

Please apply any charges not covered, or any credits, to Deposit Account number 501321 in the name of David R. Preston & Associates, having Customer Number 24232.

Respectfully submitted,

Date: June 30, 2004



David R. Preston
Reg. No. 38,710

David R. Preston & Associates, APC
12625 High Bluff Drive
Suite 205
San Diego, CA 92130
phone: 858.724.0375
facsimile: 858.724.0384



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Docket Number: GNT-00101.P.1-US	Application Number: 10/621,693
		Applicant: BUSSELL, Stuart	
		Filing Date: July 16, 2003	Group Art Unit: 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	P1	5,084,390	01/1992	Hallewell et al			
	P2	5,876,969	03/1999	Fleer et al			
	P3	6,242,570	06/2001	Sytkowski			
	P4						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	Translation
							YES NO
	F1						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EXAMINER INITIALS		CITATION
	D1	Jorgensen, J.O.L., "Human Growth Hormone Replacement Therapy: Pharmacological and Clinical Aspects," Endocrine Reviews, 12(3):189, (1991)
	D2	Putney, S.D., and P. Burke, "Improving Protein Therapeutics with Sustained-release Formulations," Nature Biotechnology, 16:153, (1998)
	D3	Johnson, O.L., et al., "A Month-long Effect from a Single Injection of Microencapsulated Human Growth Hormone," Nature Medicine, 2(7):795, (1996)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

OTHER DOCUMENTS
 (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIALS		CITATION
	D4	Chen, S.A., et al., "Plasma and Lymph Pharmacokinetics of Recombinant Human Interleukin-2 and Polyethylene Glycol-modified Interleukin-2 in Pigs," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 293(1):248, (2000).
	D5	Venkatachalam, M.A., and H. Rennke, "The Structural and Molecular Basis of Glomerular Filtration," <i>Circulation Research</i> , 43(3):337-347, (1978)
	D6	Roberts, M.J., et al., "Chemistry for Peptide and Protein PEGylation," <i>Adv Drug Deliv Rev</i> , 54(14):459-76, (2002)
	D7	Sharieff, K.A., et al., "Advances in Treatment of Chronic Hepatitis C: 'Pegylated' Interferons," <i>Cleve Clin J Med</i> , 69(2):155-9, (2002)
	D8	Lewis, R.V., et al., "Expression and Purification of a Spider Silk Protein: A New Strategy for Producing Repetitive Proteins," <i>Protein Expression and Purification</i> , 7:400-6, (1996)
	D9	Elmorjani, K., et al., "Synthetic Genes Specifying Periodic Polymers Modeled on the Repetitive Domain of Wheat Gliadins: Conception and Expression," <i>Biochemical and Biophysical Research Communication</i> , 239:240-6, (1997)
	D10	Pennell, C.A., and P. Eldin, "In vitro Production of Recombinant Antibody Fragments in <i>Pichia pastoris</i> ," <i>Res Immunol</i> , 149(6):599-603, (1998)
	D11	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--